One each in Australia, South Korea and China
Suven Life Sciences announced today that its drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators which resulted in the grant of one (1) product patent from Australia (2009355487), one (1) product patent from South Korea (10-1376145) and one (1) product patent from China (CN 102753540B) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029, 2029 and 2030 respectively.Powered by Capital Market - Live News
